Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q3 2019 Syros Pharmaceuticals Inc Earnings Call Transcript

Nov 12, 2019 / 01:30PM GMT
Release Date Price: $50.2 (+0.60%)
Operator

Good morning, ladies and gentlemen, and welcome to the Q3 2019 Syros Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions) I would now like to turn the conference over to your host, Ms. Naomi Aoki. Please go ahead.

Naomi Aoki
Syros Pharmaceuticals, Inc. - VP of Corporate Communications & IR

Thank you. This morning, we issued a press release with our third quarter 2019 financial results along with anticipated future milestones and recent accomplishments. This release is available on the Investors & Media section of Syros' website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Joe Ferra, our Chief Financial Officer. We will then open the call for questions. Dr. Eric Olson, our Chief Financial Officer; and Dr. Jeremy Springhorn, our Chief Business Officer, are also on the call and will be available for Q&A.

Before we begin, I would like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot